Result of General Meeting and Grant of Options

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Result of General Meeting and Grant of Options

The Board announces that at the General Meeting of the Company held earlier today, the resolution as set out in the Notice of Meeting was duly passed

Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM and it is expected that Admission will be effective and trading will commence at 8:00 am on 23rd November 2011.

Furthermore the Company has, pursuant to the rules of the Company's Share Option Plan 2010, granted an option to James White to subscribe for up to 2,000,000 ordinary shares in the capital of the Company at an exercise price of £0.01 per ordinary share (the "Options").

The Options will vest is three tranches (subject to the Director's discretion to waive or vary performance conditions under the terms of the Plan) as follows:

1) 667,000 options for ordinary shares will vest on the first anniversary of the date of grant of the Option ("Date of Grant");

2) 667,000 options for ordinary shares will vest on the second anniversary of the Date of Grant; and

3) 666,000 options for ordinary shares will vest on the third anniversary of the Date of Grant.

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

Hybridan LLP (Broker)

Claire Noyce +44 20 7947 4350

ZAI Corporate Finance (Nominated Adviser)

John Depasquale/ John Treacy +44 20 7060 2220

About Oxford Pharmascience Group Plc

-- Oxford Pharmascience are specialists in the repositioning of medicines via reformulation using advanced pharmaceutic technologies adding value to off patent and soon to be off patent Active Pharmaceutical Ingredients (API's).

 -- Technology portfolio includes superior chewable tablets, liquid suspensions, and solid state suspensions (soft chews) as well as drug delivery technologies to achieve either taste masking or targeted release effects.

-- Oxford Pharmascience works closely with leading academic institutions to further advance its intellectual property portfolio to apply to off patent and soon to be off patent drugs.